Cythemias
News
Adoptive T-cell therapy treats PML
Adoptive T-cell therapy has proven effective for treating progressive multifocal leukoencephalopathy (PML), according to research published in The...
News
The challenges of diagnosing CMML
DUBROVNIK, CROATIA—Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and...
News
Genomic findings may predict outcomes in MPN patients
New research suggests genomic characteristics of patients with myeloproliferative neoplasms (MPNs) can predict clinical outcomes. Investigators...
News
GPS appears to predict survival in myelofibrosis
DUBROVNIK, CROATIA—The Glasgow Prognostic Score (GPS) may predict survival in patients with myelofibrosis (MF), according to research presented at...
News
AMP publishes report on DNA variants in CMNs
A new report addresses the clinical relevance of DNA variants in chronic myeloid neoplasms (CMNs). The report is intended to aid clinical...
News
Familial risk of myeloid malignancies
A large study has revealed “the strongest evidence yet” supporting genetic susceptibility to myeloid malignancies, according to a researcher. The...
News
Tool may reveal optimal time for SCT in MF
A new tool can help patients with myelofibrosis (MF) decide when to pursue stem cell transplant (SCT), according to the MPN Research Foundation....
News
JAK inhibition linked to B-cell lymphoma
New research indicates that JAK inhibitors may increase the risk of lymphoma in patients with myelofibrosis (MF). The patients studied had a 15-...
Conference Coverage
Ropeg outperforms HU in PV patients of all ages
STOCKHOLM—Follow-up data suggest that ropeginterferon alfa-2b (ropeg) provides an advantage over hydroxyurea (HU) for patients with polycythemia...
Conference Coverage
Umbralisib can revitalize ruxolitinib in MF
STOCKHOLM—The PI3K delta inhibitor umbralisib can “augment or resurrect” responses to ruxolitinib in patients with myelofibrosis (MF), according...
News
PU-H71 receives orphan drug designation for myelofibrosis
The US Food and Drug Administration (FDA) has granted orphan drug designation to PU-H71 to treat patients with myelofibrosis. The drug...